quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:05:04·62d
INSIDERFiling
Lexeo Therapeutics Inc. logo

Amendment: Chief Operating Officer Otero Jose Manuel sold $6,684 worth of shares (721 units at $9.27), decreasing direct ownership by 1% to 63,476 units (SEC Form 4)

LXEO· Lexeo Therapeutics Inc.
Health Care
Original source

Companies

  • LXEO
    Lexeo Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Dec 18UpdateRaymond James$25.00
  • Nov 20UpdateCantor Fitzgerald$19.00
  • Oct 15UpdateGuggenheim$30.00
  • Jul 31UpdateOppenheimer$20.00
  • Jun 13UpdateRobert W. Baird$28.00
  • Jun 6UpdateH.C. Wainwright$22.00

Related

  • SEC10d
    SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.
  • INSIDER16d
    SEC Form 4 filed by Townsend Richard Nolan
  • SEC24d
    SEC Form 10-K filed by Lexeo Therapeutics Inc.
  • SEC24d
    Lexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
  • PR24d
    Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
  • INSIDER37d
    Chief Executive Officer Townsend Richard Nolan was granted 2,623 shares, increasing direct ownership by 0.67% to 395,106 units (SEC Form 4)
  • INSIDER37d
    Chief Operating Officer Otero Jose Manuel was granted 5,930 shares, increasing direct ownership by 5% to 131,390 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022